Protein Kinase Inhibitors: all 15,766 studies that test it
Page 2 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumRecruitingNCT07783412Phase 2
- Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingNCT07781449Phase 2
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07780578Phase 2
- Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory FailureNot yet recruitingNCT07779642Phase 2
- Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07778732Phase 2
- Alpelisib Challenge Test (ACT)RecruitingNCT07778524Phase 1
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingNCT07776743Phase 2
- TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07776717Phase 2
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Phase 2
- Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingNCT07773363Phase 2
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingNCT07772492Phase 3
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseNot yet recruitingNCT07771439Phase 3
- A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingNCT07770646Phase 4
- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruitingNCT07768371Phase 3
- Tucatinib Continuation StudyNot yet recruitingNCT07768358Phase 4
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
- Evaluation of PAN-90806 Eye Drops in Healthy SubjectsNot yet recruitingNCT07764965Phase 1
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingNCT07754890Phase 1/2
- STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingNCT07754734Phase 2
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingNCT07753642Phase 2
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)RecruitingNCT07753603Phase 3
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingNCT07752108Phase 3
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingNCT07750704Phase 2
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
- Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingNCT07750067Phase 2
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Phase 2
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingNCT07748208Phase 2
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingNCT07745296Phase 3
- Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNot yet recruitingNCT07745257Phase 2
- SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaRecruitingNCT07744932Phase 2
- Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male ParticipantsRecruitingNCT07744802Phase 1
- Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCLNot yet recruitingNCT07744737Phase 2
- Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCLNot yet recruitingNCT07744724Phase 2
- A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)RecruitingNCT07743671Phase 3
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingNCT07743554Phase 2
- A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT07743112Phase 2
- Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNot yet recruitingNCT07742384Phase 1
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingNCT07739914Phase 3
- Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Not yet recruitingNCT07739459Phase 2
- Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingNCT07738887Phase 2
- A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell TransfusionsNot yet recruitingNCT07738510Phase 2
- Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung DiseaseNot yet recruitingNCT07737249Phase 2
- A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07735546Phase 1
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingNCT07735533Phase 1/2
- A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)RecruitingNCT07734610Phase 1
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT07734038Phase 2
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruitingNCT07733765Phase 3
- Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingNCT07732491Phase 2
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone MetastasesNot yet recruitingNCT07731685Phase 1
- Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform StudyNot yet recruitingNCT07729917Phase 2
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingNCT07729046Phase 2
- Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell HistiocytosisNot yet recruitingNCT07728201Phase 2
- Effects of Sirolimus on Asymptomatic ApoE4 CarriersRecruitingNCT07728175Phase 1
- Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNot yet recruitingNCT07726914Phase 1
- Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and OsteosarcomaRecruitingNCT07725380Phase 1/2
- Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingNCT07724223Phase 2
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingNCT07719855Phase 3
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingNCT07719556Phase 2
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingNCT07717242Phase 2
- Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2
- Zanzalintinib in Unresectable and Progressive MPGGsNot yet recruitingNCT07714551Phase 2
- Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07714395Phase 1/2
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingNCT07714187Phase 1
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingNCT07713745Phase 2
- Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Not yet recruitingNCT07712588Phase 2/3
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 3
- Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype GlioblastomaRecruitingNCT07708961Phase 2
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingNCT07708285Phase 1/2
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2
- Selumetinib for NF2-Related SchwannomatosisNot yet recruitingNCT07707947Phase 2
- Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell TumorNot yet recruitingNCT07707882Phase 2
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNCT07706933Not applicable
- Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast CancerNot yet recruitingNCT07706179Phase 2
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT07704658Phase 4
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
- Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance DoseNot yet recruitingNCT07700446Phase 4
- A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07700056Phase 3
- A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma PatientsNot yet recruitingNCT07694973Phase 2
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07691515Phase 3
- A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07691476Phase 2
- Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
- Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell VariantEnrolling by invitationNCT07690761Phase 2
- Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07689292Phase 2
- A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRecruitingNCT07689201Phase 2
- Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid TumorsRecruitingNCT07688356Phase 2
- Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
- Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic LeukemiaRecruitingNCT07685717Phase 2
- HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07685535Phase 2
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingNCT07684950Phase 2
- A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid HemangioendotheliomaNot yet recruitingNCT07684287Phase 2
- Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidineEnrolling by invitationNCT07683949Phase 1/2
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseaseRecruitingNCT07683325Phase 2
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingNCT07682792Phase 2
- Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and NeckNot yet recruitingNCT07682675Phase 2
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)RecruitingNCT07681271Phase 2
- Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2